Literature DB >> 11884489

Quantitation of liver and spleen uptake of (99m)Tc-phytate colloid using SPECT: detection of liver cirrhosis.

David Groshar1, Gleb Slobodin, Eli Zuckerman.   

Abstract

UNLABELLED: The purpose of this study was to assess the diagnostic performance of quantitative SPECT of (99m)Tc-phytate colloid in detecting liver cirrhosis and to assess the correlation between the SPECT results and the severity of disease.
METHODS: Quantitative SPECT was performed on 60 patients (38 men, 22 women; mean age, 62.4 y) with liver cirrhosis and 36 control patients (21 men, 15 women; mean age, 58.7 y) without liver cirrhosis, and the results for the 2 groups were compared. Correlation with Child--Pugh classification and receiver operating characteristic methodology was used to analyze the results.
RESULTS: Cirrhotic livers had a lower total uptake than did control livers (35.6% plus minus 13.5% vs. 61.6% +/- 10.2%, P < 0.0001). This reduced uptake was associated with a significantly reduced percentage injected dose per cubic centimeter (%ID/cm(3)) (0.024 +/- 0.01 vs. 0.044 +/- 0.01, P < 0.0001). The volume, 1,467 +/- 348 cm(3), was similar to that of control livers (1,487 +/- 397 cm(3), P = 0.80). Total uptake in the spleen was significantly greater in patients with cirrhosis than in control patients (24.9% +/- 12% vs. 7.6% +/- 3.2%, P < 0.0001) because of an increased volume (833 +/- 460 cm(3) vs. 239 +/- 90 cm(3), P < 0.0001). The %ID/cm(3) of spleen tissue was 0.033 +/- 0.01, which was similar to the value in control patients (0.032 +/- 0.01, P = 0.88). Spleen volume showed the best performance in detecting liver cirrhosis, with a mean area under the curve of 0.97 (95% CI = 0.91--0.99). The severity of liver disease correlated better with total liver uptake (r = -0.68, 95% CI = -0.80 to -0.52, P < 0.0001).
CONCLUSION: Individual SPECT quantitation of (99m)Tc-phytate colloid uptake in the liver and spleen could be used as a noninvasive method to separate normal from cirrhotic livers and to evaluate the severity of disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11884489

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  6 in total

1.  Differential hepatic avoidance radiation therapy: Proof of concept in hepatocellular carcinoma patients.

Authors:  Stephen R Bowen; Jatinder Saini; Tobias R Chapman; Robert S Miyaoka; Paul E Kinahan; George A Sandison; Tony Wong; Hubert J Vesselle; Matthew J Nyflot; Smith Apisarnthanarax
Journal:  Radiother Oncol       Date:  2015-04-28       Impact factor: 6.280

2.  Clinical Significance of Spleen-Remnant Liver Volume Ratio in Hepatocellular Carcinoma Surgery.

Authors:  Jiang Ou; Liu Yu; Wu Wenjian; Wu Daoquan; Xu Qiang
Journal:  Indian J Surg       Date:  2013-11-17       Impact factor: 0.656

3.  Factors affecting the quantitative liver-spleen scan in normal individuals.

Authors:  John C Hoefs; Muhammad Y Sheikh; Heather Guerrero; Norah Milne
Journal:  Dig Dis Sci       Date:  2005-02       Impact factor: 3.199

4.  A study on spleen transient elastography in predicting the degree of esophageal varices and bleeding.

Authors:  Xie-Kui Wang; Ping Wang; Yong Zhang; Sheng-Lin Qi; Kun Chi; Gong-Chen Wang
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.889

5.  Measuring total liver function on sulfur colloid SPECT/CT for improved risk stratification and outcome prediction of hepatocellular carcinoma patients.

Authors:  Stephen R Bowen; Tobias R Chapman; Joshua Borgman; Robert S Miyaoka; Paul E Kinahan; Iris W Liou; George A Sandison; Hubert J Vesselle; Matthew J Nyflot; Smith Apisarnthanarax
Journal:  EJNMMI Res       Date:  2016-06-27       Impact factor: 3.138

6.  Programmed Death Ligand 1 Is Overexpressed in Liver Macrophages in Chronic Liver Diseases, and Its Blockade Improves the Antibacterial Activity Against Infections.

Authors:  Elisa Pose; Mar Coll; Celia Martínez-Sánchez; Zhutian Zeng; Bas G J Surewaard; Cristina Català; María Velasco-de Andrés; Juan José Lozano; Sílvia Ariño; David Fuster; Aida Niñerola-Bazán; Isabel Graupera; Érica Muñoz; Francisco Lozano; Pau Sancho-Bru; Paul Kubes; Pere Ginès
Journal:  Hepatology       Date:  2021-06-02       Impact factor: 17.425

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.